Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology

Clin Mol Hepatol. 2022 Oct;28(4):754-772. doi: 10.3350/cmh.2021.0394. Epub 2022 Apr 21.

Abstract

Molecular tests are necessary to stratify cancer patients for targeted therapy. However, high cost and technical barriers limit the application of these tests, hindering optimal treatment. Recently, deep learning (DL) has been applied to predict molecular test results from digitized images of tissue slides. Furthermore, treatment response and prognosis can be predicted from tissue slides using DL. In this review, we summarized DL-based studies regarding the prediction of genetic mutation, microsatellite instability, tumor mutational burden, molecular subtypes, gene expression, treatment response, and prognosis directly from hematoxylin- and eosin-stained tissue slides. Although performance needs to be improved, these studies clearly demonstrated the feasibility of DL-based prediction of key molecular features in cancer tissues. With the accumulation of data and technical advances, the performance of the DL system could be improved in the near future. Therefore, we expect that DL could provide cost- and time-effective alternative tools for patient stratification in the era of precision oncology.

Keywords: deep learning; digital pathology; molecular tests; precision medicine; precision oncology.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Deep Learning*
  • Eosine Yellowish-(YS)
  • Hematoxylin
  • Humans
  • Neoplasms* / diagnosis
  • Neoplasms* / genetics
  • Precision Medicine

Substances

  • Hematoxylin
  • Biomarkers, Tumor
  • Eosine Yellowish-(YS)